Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SenzaGen ABOSTO:SENZA -0.75%72 Operating Margin % is -14.20% as of Mar. 2026. GuruFocus rates OSTO:SENZA with a GF Score™ of 72/100 and a GF Value™ of kr6.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, SenzaGen AB ranks worse than 65.52% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. SenzaGen AB's Operating Income for the
three
months ended in Mar. 2026 was kr-2.12 Mil. SenzaGen AB's Revenue for the
three
months ended in Mar. 2026 was kr14.96 Mil. Therefore, SenzaGen AB's Operating Margin % for the quarter that ended in Mar. 2026 was -14.20%.
Good Sign:
SenzaGen AB operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for SenzaGen AB's Operating Margin % or its related term are showing as below:
OSTO:SENZA'
s Operating Margin % Range Over the Past 10 Years
Min: -2276.31 Med: -271.54 Max: -17.98
Current: -17.98
OSTO:SENZA's Operating Margin % is ranked worse than 65.52% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.35
vs OSTO:SENZA: -17.98
SenzaGen AB's 5-Year Average Operating Margin % Growth Rate was 46.00% per year.
SenzaGen AB's Operating Income for the
three
months ended in Mar. 2026 was kr-2.12 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was kr-10.66 Mil.
Warning Sign:
SenzaGen AB has never been profitable in the past 3 years. It lost money every year.
SenzaGen AB (OSTO:SENZA) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
SenzaGen AB Operating Margin % Related Terms
SenzaGen AB Operating Margin % Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SENZA vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Operating Margin % distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
SenzaGen AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (OSTO:SENZA) has a Operating Margin % of -14.20% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #133 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 65.5%.
Is SenzaGen AB's Operating Margin % too high?
SenzaGen AB's current Operating Margin % is -14.20%. Based on the distribution chart, SenzaGen AB ranks #133 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, SenzaGen AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #133 out of 203 companies for Operating Margin %. This places SenzaGen AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on SenzaGen AB and its competitors. SenzaGen AB's current Operating Margin % is -14.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
Based on GuruFocus' analysis, SenzaGen AB (OSTO:SENZA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr6.41, compared to a current price of kr5.30 — trading 17.3% below its estimated fair value. The current Operating Margin % is -14.20%. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For SenzaGen AB (OSTO:SENZA), the current Operating Margin % is -14.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (OSTO:SENZA) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of kr5.30 is trading 17.3% below its estimated GF Value™ of kr6.41.
GuruFocus considers SenzaGen AB to be Modestly Undervalued.
Key valuation signals for OSTO:SENZA:
Operating Margin %: -14.20%
GF Value™: kr6.41 vs. price of kr5.30 (17.3% below fair value)
No single metric tells the full story. See the OSTO:SENZA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for OSTO:SENZA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SENZA has been successfully added to your 
